Mechanism of Action

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that works by stimulating the release of endogenous growth hormone from the anterior pituitary gland. The available evidence indicates that tesamorelin acts through the GH-IGF1 axis, though specific molecular details are limited in the provided literature.

Based on the clinical evidence, tesamorelin functions as a growth hormone-releasing factor analog that mimics the action of natural GHRH. When administered, it binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering the release of stored growth hormone. This subsequently leads to increased production of insulin-like growth factor-1 (IGF-1), primarily in the liver, which mediates many of the therapeutic effects observed in clinical studies.

The physiological effects documented in completed clinical trials demonstrate tesamorelin's ability to reduce visceral abdominal fat in HIV-infected patients and obese individuals. Studies have also investigated its potential effects on liver fat content and overall metabolic parameters in people living with HIV, suggesting the GH-IGF1 pathway activation influences lipid metabolism and body composition.

Research has explored tesamorelin's effects beyond metabolic outcomes, including investigations into its impact on cognitive function and brain connectivity, though the specific mechanisms underlying these potential neurological effects are not detailed in the available evidence.

Evidence limitations: The provided literature does not contain detailed molecular pharmacology studies or comprehensive mechanistic data. Most references focus on clinical applications rather than fundamental mechanisms of action. The specific receptor binding kinetics, downstream signaling pathways, and detailed pharmacodynamic properties would require additional research literature for complete characterization.

This information is for educational purposes only and should not replace professional medical consultation for treatment decisions.